Evidence map›Paper›PMID 35992806›Full record

ArticleFrontiers in oncology2022

Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in glioma.

Shui-Qing Bi, Qing-Mei Zhang, Xia Zeng, Chang Liu, Wei-Xia Nong, Huan Xie, Feng Li, Li-Na Lin, Bin Luo, Ying-Ying Ge and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Shui-Qing BiDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Qing-Mei ZhangDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Xia ZengDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Chang LiuDepartment of Neurosurgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.
Wei-Xia NongDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Huan XieDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Feng LiDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Li-Na LinDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Bin LuoDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Ying-Ying GeDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Xiao-Xun XieDepartment of Histology and Embryology, School of Preclinical Medicine, Guangxi Medical University, Nanning, Guangxi, China.
Guangxi Medical University · CNGuangxi Zhuang Autonomous Region Department of Education · CNFirst Affiliated Hospital of GuangXi Medical University · CNThe People's Hospital of Guangxi Zhuang Autonomous Region · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The study evaluated the efficacy of combined epigenetic drugs of decitabine (DAC), valproic acid (VPA), and trichostatin A (TSA) on immunotherapy against glioma. Methods: The expression and prognosis of MAGE-D4 in glioma were analyzed online, and the expression of MAGE-D4 and HLA-A2 in glioma induced by epigenetic drugs was detected by qRT-PCR, Western blot, and flow cytometry. The methylation status of the MAGE-D4 promoter was determined by pyrosequencing. An HLA-A2 restricted MAGE-D4 peptide was predicted and synthesized. An affinity assay and a peptide/HLA complex stability assay were performed to determine the affinity between peptide and HLA. CCK8 assay, CFSE assay, ELISA and ELISPOT were performed to detect the function of MAGE-D4 peptide-specific T cells. Flow cytometry, ELISA, and cytotoxicity assays were used to detect the cytotoxicity effect of MAGE-D4 peptide-specific T cells combined with epigenetic drugs against glioma Results: MAGE-D4 was highly expressed in glioma and correlated with poor prognosis. Glioma cells could be induced to express MAGE-D4 and HLA-A2 by epigenetic drugs. MAGE-D4-associated peptides were found that induce DCs to stimulate the highest T-cell activities of proliferation, IL-2 excretion, and IFN-γ secretion. MAGE-D4 peptide-specific T cells treated with TSA only or combining TSA and DAC had the most cytotoxicity effect, and its cytotoxicity effect on glioma cells decreased significantly after HLA blocking. Conclusion: MAGE-D4 is highly expressed in glioma and correlated with the prognosis of glioma. The novel MAGE-D4 peptide identified was capable of inducing MAGE-D4-specific T cells that can effectively inhibit glioma growth, and the epigenetic drug application can enhance this inhibition.

Indexed as

cytotoxic T lymphocytedecitabinegliomaMAGE-D4trichostatin Avalproic acid

Identifiers

PMID35992806
PMCPMC9382192
OpenAlexW4289517398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.